Eli Lilly has bolstered its position the fast-emerging area of protein degrader drugs, agreeing a $1.6 billion-plus deal with Lycia Therapeutics spanning up to five drug targets.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback